Report cover image

U.S. Real-World Evidence (RWE) Solutions Market by Component [Datasets (Clinical, Claims, Pharmacy, Integrated), Services], Application (Market Access, Oncology, Neurology, Post Market Surveillance), End User (Pharma Companies, Providers) - Forecast to 20

Publisher Meticulous Market Research
Published Feb 09, 2022
Length 115 Pages
SKU # METI16972821

Description

U.S. Real-World Evidence (RWE) Solutions Market by Component [Datasets (Clinical, Claims, Pharmacy, Integrated), Services], Application (Market Access, Oncology, Neurology, Post Market Surveillance), End User (Pharma Companies, Providers)

The U.S. RWE solutions market is expected to grow at a CAGR of 13.0% from 2021 to 2028 to reach $2.01 billion by 2028

Following a thorough secondary and primary research and in-depth analysis of the market scenario, the report carries out the key industry drivers, restraints, challenges, and opportunities

Growing incidence of chronic & infectious diseases, delays in drug development and the subsequent increase in development costs, rising focus towards personalized healthcare, a shift from volume to value-based care, and rapidly growing big data in healthcare are the key factors driving steady growth in the U.S. RWE solutions market. Further, significant opportunities for existing market players and new entrants are provided by rising focus on end-to-end RWE services, and rising adoption of wearable devices and AI in RWE

Based on component, the datasets segment commanded the largest share in the market in 2021. Real-world data (RWD) are derived from various sources associated with outcomes in a heterogeneous patient population in real-world settings. Datasets are present in a secondary format on which retrospective studies are conducted to generate real-world evidence. This real-world evidence provides meaningful insights into unmet needs and the clinical and economic impacts on patients and healthcare systems. It also determines the outcomes based on much larger data samples, reduces costs, and improves the efficiency of clinical trials.

Based on application, the drug development & approvals segment is expected to show the fastest growth rate in the forecast period. Factors attributing towards the growth of this segment are increasing demand for real-world data and real-world evidence to accelerate drug discovery and development, and increasing investments by biopharmaceutical companies in R&D.

In the field of drug development, quality-of-life metrics, and Patient-Reported Outcome Measures (PROMs) are now becoming common elements in clinical trials. The evidence generated from real-world data is regularly utilized to inform aspects of drug development. The role of RWE in drug development is expanding as RWE studies are significantly less costly and time-consuming than RCTs, providing easier access to long-term effectiveness data and helping overcome some of the feasibility barriers of running RCTs.

Based on end user, the pharmaceutical & medical device companies segment is expected to show the fastest growth rate in the forecast period. The growth of this segment is primarily attributed to the increasing importance of RWE studies in drug development & approvals and the growing need to avoid costly drug recalls and assess drug performance in real-world settings.

The cost of developing a new drug was more than ~USD 2,600 million in 2020 compared to USD 802 million in 2003. This increase in drug development costs reflects various technical, regulatory, and economic challenges pharmaceutical R&D pipelines face.

The key companies operating in the U.S. RWE solutions market are IQVIA HOLDINGS INC. (U.S.), ICON plc (Ireland), PPD, Inc. (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), IBM Corporation (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), Flatiron Health (U.S.), SYNEOS HEALTH, INC. (U.S.), CLARIVATE PLC (U.S.), Medpace Holdings, Inc. (U.S.), and Symphony Innovation, LLC (U.S.).

Scope of the Report

U.S. RWE Solutions Market, by Component
Datasets
Disparate Datasets
EMR/EHR/Clinical Data
Claims & Billing Data
Pharmacy Data
Product/Disease Registries Data
Other Disparate Datasets
Integrated Datasets
Consulting and Analytics

(Note – Other Disparate Datasets include data generated from mobile devices, wearable devices, and social media)

U.S. RWE Solutions Market, by Application

Market Access & Reimbursement/Coverage Decisions
Drug Development & Approvals
Oncology
Neurology
Immunology
Cardiovascular Diseases
Other Therapeutic Areas
Post Market Surveillance
Medical Device Development & Approvals
Other Applications

(Note – Other Therapeutic Areas include infectious diseases, musculoskeletal disorders, dermatological diseases, and respiratory diseases/ Other Applications include regulatory and clinical decision-making)

U.S. RWE Solutions Market, by End User

Pharmaceutical, Biotechnology, and Medical Device Companies
Healthcare Payers
Healthcare Providers
Other End Users

(Note – Other end users include academic research institutions, patient advocacy groups, regulators, and health technology assessment agencies)

Table of Contents

115 Pages
1. Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency
2. Research Methodology
2.1. Research Process
2.2. Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research
2.3. Market Assessment
2.3.1. Market Size Estimation
2.3.1.1. Bottom-Up Approach
2.3.1.2. Top-Down Approach
2.3.1.3. Growth Forecast
2.3.2. Market Share Analysis
2.4. Assumptions for the Study
2.5. Limitations for the Study
3. Executive Summary
4. Market Insights
4.1. Market Overview
4.2. Drivers
4.2.1. Growing Burden of Chronic and Infectious Diseases
4.2.2. Rising Focus Towards Personalized Healthcare
4.2.3. Delays in Drug Development and the Subsequent Increase in Development Costs
4.2.4. Shift Towards Value-Based Care
4.2.5. Rapidly Growing Big Data in Healthcare
4.3. Restraints
4.3.1. Reluctance to Rely on Real-World Studies
4.4. Opportunities
4.4.1. Rising Focus on End-to-End RWE Services
4.4.2. Rising Adoption of Wearable Devices and Artificial Intelligence in RWE
4.5. Challenges
4.5.1. Lack of Standardized Methodologies to Develop RWE
4.6. Key Market Trends
4.6.1. Growing Adoption of RWE in Drug Development and Commercialization
4.6.2. Rising Number of Consolidations
4.6.3. Improved Patient Outcomes and Value Creation from Real-World Evidence
4.7. Impact Assessment of COVID-19 on the U.S. RWE Solutions Market
5. Regulatory Analysis – U.S. Real-World Evidence (RWE) Solutions Market
6. Pricing Models (EMR/Genomic/Integrated Datasets)
6.1. Introduction
6.2. Pay Per Patient Record (Volume-Based Pricing)
6.3. Pay Per Usage (Value-Based Pricing)
6.4. Annual Subscription
7. U.S. Real-World Evidence Solutions Market, by Component
7.1. Introduction
7.2. Datasets
7.2.1. Disparate Datasets
7.2.1.1. EMR/EHR/Clinical Data
7.2.1.2. Claims & Billing Data
7.2.1.3. Pharmacy Data
7.2.1.4. Product/Disease Registries Data
7.2.1.5. Other Disparate Datasets
7.2.2. Integrated Datasets
7.3. Consulting & Analytics
8. U.S. Real-World Evidence Solutions Market, by Application
8.1. Introduction
8.2. Market Access & Reimbursement/Coverage Decisions
8.3. Drug Development & Approvals
8.3.1. Oncology
8.3.2. Neurology
8.3.3. Immunology
8.3.4. Cardiovascular Diseases
8.3.5. Other Therapeutic Areas
8.4. Medical Device Development & Approvals
8.5. Post-Market Surveillance
8.6. Other Applications
9. U.S. Real-World Evidence Solutions Market, by End User
9.1. Introduction
9.2. Pharmaceutical, Biotechnology, and Medical Device Companies
9.3. Healthcare Payers
9.4. Healthcare Providers
9.5. Other End Users
10. Competitive Landscape
10.1. Introduction
10.2. Key Growth Strategies
10.3. Competitive Benchmarking
10.4. Market Share Analysis (2020)
10.4.1. IQVIA Holdings, Inc. (U.S.)
10.4.2. ICON plc (Ireland)
10.4.3. PPD, Inc. (U.S.)
11. Company Profiles
11.1. IQVIA HOLDINGS INC.
11.1.1. Business Overview
11.1.2. Financial Overview
11.1.3. Solution Portfolio
11.1.4. Strategic Developments
11.2. PPD, Inc.
11.2.1. Business Overview
11.2.2. Financial Overview
11.2.3. Solution Portfolio
11.2.4. Strategic Developments
11.3. ICON Plc
11.3.1. Business Overview
11.3.2. Financial Overview
11.3.3. Solution Portfolio
11.3.4. Strategic Developments
11.4. Parexel International Corporation
11.4.1. Business Overview
11.4.2. Solution Portfolio
11.4.3. Strategic Developments
11.5. IBM Corporation
11.5.1. Business Overview
11.5.2. Financial Overview
11.5.3. Solution Portfolio
11.5.4. Strategic Developments
11.6. UnitedHealth Group Incorporated
11.6.1. Business Overview
11.6.2. Financial Overview
11.6.3. Solution Portfolio
11.7. Flatiron Health
11.7.1. Business Overview
11.7.2. Solution Portfolio
11.7.3. Strategic Developments
11.8. Oracle Corporation
11.8.1. Business Overview
11.8.2. Financial Overview
11.8.3. Solution Portfolio
11.9. SAS Institute, Inc.
11.9.1. Business Overview
11.9.2. Solution Portfolio
11.9.2.1. Strategic Developments
11.10. Clinigen Group plc
11.10.1. Business Overview
11.10.2. Financial Overview
11.10.3. Solution Portfolio
11.11. Cognizant Technology Solutions Corporation
11.11.1. Business Overview
11.11.2. Financial Overview
11.11.3. Solution Portfolio
11.12. PerkinElmer, Inc.
11.12.1. Business Overview
11.12.2. Financial Overview
11.12.3. Solution Portfolio
11.13. SYNEOS HEALTH, INC.
11.13.1. Business Overview
11.13.2. Financial Overview
11.13.3. Service Portfolio
11.13.4. Strategic Developments
11.14. CLARIVATE PLC
11.14.1. Business Overview
11.14.2. Financial Overview
11.14.3. Service Portfolio
11.15. Medpace Holdings, Inc.
11.15.1. Business Overview
11.15.2. Financial Overview
11.15.3. Service Portfolio
11.16. Symphony Innovation, LLC
11.16.1. Business Overview
11.16.2. Service Portfolio
11.16.3. Strategic Developments
11.17. Veeva Systems Inc.
11.17.1. Business Overview
11.17.2. Financial Overview
11.17.3. Solution Portfolio
11.17.4. Strategic Developments
11.18. Sensyne Health plc
11.18.1. Business Overview
11.18.2. Financial Overview
11.18.3. Solution Portfolio
11.18.4. Strategic Developments
11.19. Prognos Health Inc.
11.19.1. Business Overview
11.19.2. Solution Portfolio
11.19.3. Strategic Developments
11.20. HealthVerity Inc.
11.20.1. Business Overview
11.20.2. Solution Portfolio
11.20.3. Strategic Developments
11.21. Truveta Inc.
11.21.1. Business Overview
11.21.2. Solution Portfolio
11.21.3. Strategic Developments
12. Appendix
12.1. Questionnaire
12.2. Available Customization
List of Tables
Table 1 U.S. Real-World Evidence Solutions Market Drivers: Impact Analysis (2021-2028)
Table 2 Total Per-Study Cost (In Usd Million), by Phase and Therapeutic Area
Table 3 Sources of Healthcare Data
Table 4 U.S. Real-World Evidence Solutions Market Restraints: Impact Analysis (2021-2028)
Table 5 Observed Indicative Prices of Real-World Data by Type (USD Per Patient Record)
Table 6 U.S. Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 7 U.S. Real-World Evidence Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 8 U.S. RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 9 U.S. Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 10 U.S. RWE Solutions Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 11 Estimated Number of New Cancer Cases in the U.S. (2019–2023)
Table 12 Medical Costs Associated With Cardiovascular Diseases (2010-2030) (USD Billion)
Table 13 Other Therapeutic Areas: Drugs in the R&D Pipeline
Table 14 U.S. RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 15 Recent Developments, by Company, 2018–2021
List of Figures
Figure 1 Key Stakeholders
Figure 2 Research Process
Figure 3 Key Secondary Sources
Figure 4 Primary Research Techniques
Figure 5 Key Executives Interviewed
Figure 6 Breakdown of Primary Interviews (Supply-Side & Demand-Side)
Figure 7 Market Size Estimation
Figure 8 U.S. Real-World Evidence Solutions Market, by Component, 2021 Vs. 2028 (USD Million)
Figure 9 U.S. Real-World Evidence Solutions Market, by Application, 2021 Vs. 2028 (USD Million)
Figure 10 U.S. Real-World Evidence Solutions Market, by End User, 2021 Vs. 2028 (USD Million)
Figure 11 Market Dynamics
Figure 12 Number of People in the U.S. With Chronic Conditions (2000–2030)
Figure 13 Percentage of Personalized Medicines Approved (2015-2020)
Figure 14 U.S. Real-World Evidence Solutions Market Size, by Component, 2021–2028 (USD Million)
Figure 15 U.S.: Number of E-Prescriptions, 2013–2020 (Billions)
Figure 16 U.S. Real-World Evidence Solutions Market Size, by Application, 2021–2028 (USD Million)
Figure 17 Dalys of Neurological Disorders in the U.S., 2010–2021 (In Thousands)
Figure 18 U.S.: Hepatitis A Virus (HAV) Infections, 2013–2020
Figure 19 U.S. Real-World Evidence Solutions Market Size, by End User, 2021–2028 (USD Million)
Figure 20 U.S. Pharmaceutical R&D Spending, 1980–2019 (USD Billion)
Figure 21 Key Growth Strategies Adopted by Leading Players (2018–2021)
Figure 22 U.S. Real-World Evidence Solutions: Competitive Benchmarking
Figure 23 Market Share Analysis: U.S. Real-World Evidence Solutions Industry (2020)
Figure 24 IQVIA HOLDINGS INC.: Financial Overview (2020)
Figure 25 PPD, Inc.: Financial Overview (2020)
Figure 26 ICON Plc: Financial Overview (2020)
Figure 27 IBM Corporation: Financial Overview (2020)
Figure 28 UnitedHealth Group Incorporated: Financial Overview (2020)
Figure 29 Oracle Corporation: Financial Overview (2021)
Figure 30 Clinigen Group plc: Financial Overview (2021)
Figure 31 Cognizant Technology Solutions Corporation: Financial Overview (2020)
Figure 32 PerkinElmer, Inc.: Financial Overview (2020)
Figure 33 SYNEOS HEALTH, INC.: Financial Overview (2020)
Figure 34 CLARIVATE PLC: Financial Overview (2020)
Figure 35 Medpace Holdings, Inc.: Financial Overview (2020)
Figure 36 Veeva Systems Inc.: Financial Overview (2021)
Figure 37 Sensyne Health plc: Financial Overview (2020)

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us